Our goal for the year was simple: Identify and trade the best-looking classical chart set-ups. We've broken it into sections by chart pattern and the best set-ups in those patterns.

BeiGene, a Beijing cancer biopharma, announced a blockbuster collaboration with Amgen. I-Mab, a Shanghai biopharma, has filed to IPO; Aesthetic Medical International Holdings, a Shenzhen aesthetics company, completed a $30 million IPO on NASDAQ.